Yahoo Web Search

  1. It has been about a month since the last earnings report for Aduro Biotech (ADRO). Will the recent negative trend continue leading up to its next earnings release, or is Aduro Biotech due for ...

  2. J&J's Stelara Gets Approval in EU for Ulcerative Colitis

    Zacks via Yahoo FinanceSep 05 14:18 PM

    Johnson & Johnson JNJ announced that the European Commission (EC) has approved the label expansion of Stelara (ustekinumab) for the treatment of adults with moderately-to-severely active ulcerative ...

  3. Merck, Pfizer Slide on Pelosi’s ‘Scary’ Drug-Pricing Plan

    Bloomberg via Yahoo FinanceSep 10 14:00 PM

    Drugmakers from Merck & Co. to Pfizer Inc. were under pressure in Tuesday's trading after documents showed House leader Nancy Pelosi's drug pricing plan appears skewed “to the more aggressive ...

  4. This weekend's Barron's cover story offers a look at biotechnology companies developing cutting-edge drugs. Other featured articles discuss the outlook for stocks and bonds in the fall and how to play ...

  5. Pfizer's Pneumococcal Vaccine Shows Potential in Infants

    Zacks via Yahoo FinanceSep 10 22:06 PM

    Pfizer Inc. PFE announced encouraging data from a phase II study evaluating its 20-valent pneumococcal conjugate vaccine (20vPnC) candidate, PF-06482077, in healthy infants. The proof-of-concept ...

  6. UPDATE 1-Novo Nordisk to cut insulin prices in the U.S.

    Reuters via Yahoo FinanceSep 06 13:14 PM

    Novo Nordisk will offer cheaper insulin to U.S. diabetics, the Danish drugmaker said on Friday, in response to criticism over the high price of the medication and after similar moves by rivals ...

  7. Developed by Eli Lilly and Co's Loxo Oncology and marketed by German drugmaker Bayer, it fights a rare genetic mutation that appears in less than 1% of solid tumors, regardless ...

  8. Lexicon (LXRX) Settles With Sanofi for $260M, Shares Rally

    Zacks via Yahoo FinanceSep 11 13:46 PM

    Lexicon Pharmaceuticals, Inc. LXRX announced that it will regain re-gain global rights to diabetes drug, Zynquista (sotagliflozin), and will receive $260 million from Sanofi SNY per the terms ...

  9. Leaner Pfizer Positioned to Boost R&D Output

    GuruFocus.com via Yahoo FinanceSep 11 19:50 PM

    If it's true that busy hands are happy hands, then the management team at Pfizer Inc. (NYSE:PFE) must be ecstatic. Agreed to spin off Upjohn, the manufacturer of Pfizer's drugs that no longer ...

  10. Eli Lilly and Co's Trulicity, an injectable rival, has a list price of $759.40 per month, according to Lilly's website.

  1. Ads
    related to Eli Lilly